Drug Profile

HIV vaccine - NuGenerex Immuno-Oncology

Alternative Names: AE-298p; AE-H vaccine

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Antigen Express
Developer NuGenerex Immuno-Oncology
Class AIDS vaccines
Mechanism of Action Helper-inducer T-lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

No development reported HIV infections

Most Recent Events

28 Apr 2018 No recent reports of development identified for phase-I development in HIV-infections in USA (Parenteral)
08 Feb 2017 HIV vaccine - Antigen Express is available for licensing as of 08 Feb 2017. http://www.antigenexpress.com/ (Antigen Express pipeline, February 2017)
19 Apr 2016 Phase I development is ongoing in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com